Pfizer, Inc. (PFE) Shares Sold by Howard Capital Management

Howard Capital Management reduced its position in Pfizer, Inc. (NYSE:PFE) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 85,191 shares of the biopharmaceutical company’s stock after selling 1,390 shares during the period. Howard Capital Management’s holdings in Pfizer were worth $2,862,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Asset Planning Services Ltd. increased its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the last quarter. D. Scott Neal Inc. increased its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Orrstown Financial Services Inc. increased its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new stake in Pfizer during the first quarter worth about $121,000. Finally, Cable Hill Partners LLC increased its stake in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the last quarter. Institutional investors own 69.94% of the company’s stock.

Pfizer, Inc. (NYSE:PFE) traded up 0.498% during mid-day trading on Wednesday, reaching $33.315. 6,431,823 shares of the company’s stock traded hands. The firm has a market cap of $198.14 billion, a PE ratio of 24.371 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.38. The firm has a 50 day moving average of $33.28 and a 200 day moving average of $33.41.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.64 EPS. Analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.86%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is 94.12%.

COPYRIGHT VIOLATION WARNING: “Pfizer, Inc. (PFE) Shares Sold by Howard Capital Management” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/08/23/pfizer-inc-pfe-shares-sold-by-howard-capital-management.html.

A number of equities research analysts have issued reports on the stock. Berenberg Bank reiterated a “hold” rating and issued a $36.00 target price (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Jefferies Group LLC restated a “hold” rating and set a $35.00 price target on shares of Pfizer in a research note on Friday, August 18th. Finally, UBS AG restated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $37.61.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply